# Immunicon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunicon

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.immunicon.com
- Total disclosed funding: $25M
- Latest round: Series F (Jul 11, 2003)
- Investors on record: 11

## About

Immunicon is a healthcare technology company that specializes in developing advanced diagnostic solutions to enhance cancer detection and improve patient management.Founded in 1983 and headquartered in the US, Immunicon focuses on the development of technologies for cancer diagnostics. The company completed its most recent funding round, a Trade Sale, in April 2004, raising USD 31.00 mn, with Veridex, LLC as the investor. The firm has been involved in 11 deals, showcasing its activity in the healthcare sector.Immunicon.com specializes in offering innovative solutions aimed at enhancing the efficiency and accuracy of diagnostic processes in the healthcare sector. Their core product offerings focus on advanced technologies for cancer diagnostics, including proprietary assays and detection systems that streamline the identification of circulating tumor cells (CTCs) in blood samples. These products cater to a diverse range of healthcare providers, ensuring that their technologies meet the needs of a global clientele, ultimately improving patient outcomes by facilitating earlier and more accurate cancer detection.In the most recent year, 2007, Immunicon reported a revenue of USD 16.09 mn, while experiencing an EBITDA loss of USD 31.32 mn.Immunicon plans to leverage its recent funding from the Trade Sale completed in April 2004 to advance the development of new diagnostic products aimed at enhancing cancer detection. The company is targeting expansion into markets across North America and Europe, with specific strategies to increase its presence in Asia by 2025. Upcoming product launches are expected to include innovative assays designed to further streamline CTC detection processes.

## Funding rounds

- Series F, Jul 11, 2003, $25M — Burrill & Company, TL Ventures, Canaan Partners, Foundation Medical Partners, Wheatley Partners, Anthem Capital, Johnson & Johnson Innovation, MedCapital, Equity4Life, Claneil Enterprises, Inc., Lumira Ventures

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series F
- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series F
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series F
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series F
- Wheatley Partners (https://capitalatlas.ai/funds/wheatley-partners) — Series F
- Anthem Capital (https://capitalatlas.ai/funds/anthem-capital) — Series F
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series F
- MedCapital — Series F
- Equity4Life (https://capitalatlas.ai/funds/equity4life) — Series F
- Claneil Enterprises, Inc. — Series F
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series F